

Schrödinger and ShanghaiTech University to Establish Center of Excellence (COE) and Form Strategic Partnership

11/16/2017

NOTE: This contains archival information which should not be considered current.

Collaboration to Focus on Computational Chemistry and Molecular Recognition in the Human Body

NEW YORK, NY and SHANGHAI, CHINA (November 7, 2017) – Schrödinger, Inc., a world-leading provider of advanced molecular simulations and drug discovery software solutions, and ShanghaiTech University in China have reached an agreement to develop a strategic partnership and establish the Shanghai Center of Excellence (COE) in Computational Chemistry at ShanghaiTech University.

Schrödinger and ShanghaiTech University will embark on joint research projects to solve challenging scientific problems in molecular recognition of the human body that can lead to co discoveries. Under the terms of the agreement, Schrödinger will provide software as well as educational and training support to researchers at the COE. Three entities at ShanghaiTech University – iHuman Institute, Shanghai Institute for Advanced Immunochemical Studies, and the Library – will share joint priority access to Schrödinger’s software, with iHuman Institute leading the collaboration with Schrödinger.

“Schrödinger is a world leader in the area of computational chemistry. We are thrilled to be partnering with them in our mission to both train and mentor the next generation of scientific global leaders in the area of computational chemistry,” said Professor Ray Stevens, iHuman Institute’s Founding Director and one of the key architects of the strategic partnership. “Schrödinger’s software will be a key element in helping us build an atomic resolution model of the human body to better understand disease states and potentially develop new and better medicines.”

“We are very pleased to be collaborating with ShanghaiTech University’s leading scientists in the field of molecular recognition in the human body to accelerate the understanding/discovery novel molecules that have the potential to treat unmet biomedical needs,” said Schrödinger’s President and CEO, Dr. Ramy Farid, “We believe our industry-leading platform can play an important role in helping ShanghaiTech achieve its goal of innovation in China.”

#

About Schrödinger

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech companies Nimbus Therapeutics, Morphic Therapeutic, and others. Schrödinger’s investors include David E. Shaw and Bill Gates. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrödinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schrödinger has over 300 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.

About ShanghaiTech University

ShanghaiTech seeks innovative solutions to address the challenges that China is facing in the field of energy, material, environment, human health, thus to improve productivity driven by innovation, and contribute to the restructuring and development of China.

Schrödinger Contacts:

Investors:

Christina Tartaglia

Stern Investor Relations, Inc.

Tel: +1 212 362 1200

Email: christina@sternir.com

Media:

Shi-Yi Liu, Ph.D.

Tel: +1 503 299 1150 x108

Email: shi-yi.liu@schrodinger.com